- Home
- KIDS vs EYPT Comparison
KIDS vs EYPT Comparison
Compare KIDS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.6M | 1.5B |
| IPO Year | 2016 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KIDS | EYPT |
|---|---|---|
| Price | $16.52 | $13.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $24.67 | ★ $31.80 |
| AVG Volume (30 Days) | 136.9K | ★ 1.3M |
| Earning Date | 05-06-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,049,000.00 | $7,539,000.00 |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | $1,031.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $15.34 | $3.91 |
| 52 Week High | $26.40 | $19.11 |
Technical Indicators
Market Signals| Indicator | KIDS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 37.90 |
| Support Level | $16.11 | $12.05 |
| Resistance Level | $19.15 | $13.32 |
| Average True Range (ATR) | 0.93 | 1.01 |
| MACD | -0.18 | -0.34 |
| Stochastic Oscillator | 5.56 | 4.23 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.